- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Fat transfer.
Displaying page 1 of 1.
EudraCT Number: 2017-004319-37 | Sponsor Protocol Number: 001.4 | Start Date*: 2019-06-19 | |||||||||||
Sponsor Name:Medical University of Vienna, Department of Surgery | |||||||||||||
Full Title: A prospective, randomised, single-blind explorative study to investigate the efficacy and safety of fat graft enrichment with autologous platelet lysate in female breast augmentation | |||||||||||||
Medical condition: Fat grafting e.g. to the breast to restore small tissue defects is a very common and safe surgical procedure. Its main success among other is depended on the survival rate of the transferred fat ti... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005473-36 | Sponsor Protocol Number: Dezember2014Version2 | Start Date*: Information not available in EudraCT |
Sponsor Name:Universitätsklinikum Freiburg | ||
Full Title: Modeling of lipoprotein in patients with familial hypercholesterolemia compared to healthy subjects | ||
Medical condition: familial hypercholesterolemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-008899-14 | Sponsor Protocol Number: LWH0776 | Start Date*: 2009-06-25 |
Sponsor Name:Liverpool Women's NHS Foundation Trust | ||
Full Title: Standardised, Concentrated, Additional Macronutrients, Parenteral (SCAMP) nutrition in very preterm infants: a phase IV randomised controlled study of macronutrient intake, growth and implications ... | ||
Medical condition: Prematurity | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-023742-79 | Sponsor Protocol Number: AEG 733-012 | Start Date*: 2011-03-25 | |||||||||||
Sponsor Name:AEGERION PHARMACEUTICALS | |||||||||||||
Full Title: A Phase III, Long Term, Open Label, Follow on Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor ‘lomitapide’ (AEGR-733) in Patients with Homozygous Familial Hypercholesterolemia | |||||||||||||
Medical condition: Homozygous Familial Hypercholesterolemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-007058-36 | Sponsor Protocol Number: 733-005 | Start Date*: 2009-06-25 | |||||||||||
Sponsor Name:Aegerion Pharmaceuticals | |||||||||||||
Full Title: A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients with Homozygous Familial Hypercholesterolemia on Current Lipid-lowering Therapy | |||||||||||||
Medical condition: Homozygous Familial Hypercholesterolemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004083-21 | Sponsor Protocol Number: E7438-G000-101 | Start Date*: 2015-02-02 |
Sponsor Name:Epizyme, Inc. | ||
Full Title: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas | ||
Medical condition: Relapsed or refractory Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Advanced solid tumor | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-004554-42 | Sponsor Protocol Number: TAMDMD | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:University of Basel Children's Hospital, Division of Neuropediatrics | |||||||||||||
Full Title: Tamoxifen in Duchenne muscular dystrophy: A multicenter, randomised, double-blind, placebo-controlled, phase 3 safety and efficacy 48-week trial Tamoxifen in Duchenne muscular dystrophy: A 48-week... | |||||||||||||
Medical condition: Duchenne muscular dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (GB - no longer in EU/EEA) FR (Completed) ES (Prematurely Ended) NL (Prematurely Ended) BE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
